Application of encapsulated cell technology for retinal degenerative diseases.
about
Emerging gene therapies for retinal degenerationsTherapeutic potential of optogenetic neuromodulationCNTF induces regeneration of cone outer segments in a rat model of retinal degenerationLong-term efficacy of ciliary muscle gene transfer of three sFlt-1 variants in a rat model of laser-induced choroidal neovascularizationCNTF and retinaEffect of CNTF on retinal ganglion cell survival in experimental glaucomaFunctional cone rescue by RdCVF protein in a dominant model of retinitis pigmentosa.Retinitis pigmentosa and allied conditions today: a paradigm of translational researchOcular delivery of macromoleculesConstruction of a eukaryotic expression plasmid for human retina-derived neurotrophin-3.CNGB3-achromatopsia clinical trial with CNTF: diminished rod pathway responses with no evidence of improvement in cone functionCiliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration.Fibrosis and diseases of the eye.Reduction of amyloid-beta levels in mouse eye tissues by intra-vitreally delivered neprilysinNew therapeutic targets in atrophic age-related macular degeneration.Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.Phenotypic variation and genotype-phenotype discordance in canine cone-rod dystrophy with an RPGRIP1 mutation.Redefining tissue engineering for nanomedicine in ophthalmology.Emerging therapeutic approaches in the management of retinal angiogenesis and edema.Clinical and Rehabilitative Management of Retinitis Pigmentosa: Up-to-Date.Advances in ocular drug delivery: emphasis on the posterior segment.Neurotrophin family members as neuroprotectants in retinal degenerations.Stem cells in clinical trials for treatment of retinal degeneration.Recent developments in ocular drug delivery.Extended ocular drug delivery systems for the anterior and posterior segments: biomaterial options and applications.Drug delivery to the eye: what benefits do nanocarriers offer?Retinal expression of Fgf2 in RCS rats with subretinal microphotodiode array.Combination therapies in ophthalmology: implications for intravitreal delivery.When is macular edema not macular edema? An update on macular telangiectasia type 2.An ADAM9 mutation in canine cone-rod dystrophy 3 establishes homology with human cone-rod dystrophy 9Switching on the lights: the use of optogenetics to advance retinal gene therapy.Regeneration of cone outer segments induced by CNTF.Ciliary neurotrophic factor (CNTF) delivery to retina: an overview of current research advancements.How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches.Protective effects of the neuropeptide PACAP in diabetic retinopathy.
P2860
Q26853366-768A1385-5DE2-4F37-9EC0-1C5DFE408839Q28084334-26495B17-33BA-4108-87EF-AD95E4CA374CQ28572876-58A4A2A6-873C-4416-A6A6-A8638148C031Q28582445-63ECA6DB-2C07-499F-B144-70BEE7EF38B8Q28731691-B89CB56F-CC9A-4094-8C2E-75A464D26A07Q33390314-BB769B8F-D308-49D9-8EC3-F70ED0F90C10Q33713504-C67FB660-D50B-402A-9873-F9A98C2FB702Q33918834-70223653-C575-42D7-B4AA-7CEE6EE4178FQ34079676-B732B5F0-BA0A-46FF-9A8C-9A327A9CC83AQ34094461-6B053ECA-93D1-4186-A0F9-045482644921Q34312144-95C3CEDA-427D-436F-ABD2-8EC14B6436CDQ34794630-CD42F9A3-7E23-4568-AB1A-7A0BDE670253Q35649477-988501D0-32AA-4E9E-9BBF-ACEC5CA37EC6Q36319298-106FCB9F-A97B-4B84-AABE-E7715E0118D8Q36804427-5DF04376-F3BC-4ABF-B949-1578EA48A28FQ37109083-69A745D9-CD92-4A99-A479-02158E996310Q37425238-B4F599E3-ADA9-49DA-9927-2276737761B6Q37782373-E568B704-DD41-474E-8ACE-5C8FB8EC01A7Q37822290-17C56901-2180-4EE5-A980-A5253CCD5EAFQ37963356-6792AA83-6AAD-4046-BF8D-616561AB0009Q38224320-70C4A158-6198-4082-AFD5-68004D4E1A24Q38269424-92E5663E-3C13-4D7C-AD3B-6D1C22B48B63Q38594426-3CF41FD5-E81C-4481-BF52-A8EFA64A5577Q38603354-44663863-B15E-4A43-ACD5-E2349C574A43Q38934604-05049532-9FDB-4869-B562-563341C1FB8BQ39130097-9FB28345-DBCB-4748-9B48-4D721B36049DQ39352997-727D2304-6011-4E3A-B9BC-DC3271463862Q42008678-4E8DD4AF-5B51-4F4C-8976-979033BD3CE7Q42359936-400A6546-6C72-466E-8783-0A0D674F94B5Q42522157-18F0D90F-0C6F-42B6-B2AF-D4A359170FC1Q42786548-0210C4DA-7FB3-452B-91C5-CE2EF0CCBDB7Q42935416-B9882F42-A973-4489-AAC5-75DBDC29C12AQ47601916-0DC8B18A-E0B7-4DB5-ADF0-1DE4D9C8D747Q48902538-88E5A91B-7B9B-494C-9312-ED772B621DBEQ54323129-7F7E7760-FACB-4D40-9E04-96F0A16CED45
P2860
Application of encapsulated cell technology for retinal degenerative diseases.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Application of encapsulated cell technology for retinal degenerative diseases.
@ast
Application of encapsulated cell technology for retinal degenerative diseases.
@en
type
label
Application of encapsulated cell technology for retinal degenerative diseases.
@ast
Application of encapsulated cell technology for retinal degenerative diseases.
@en
prefLabel
Application of encapsulated cell technology for retinal degenerative diseases.
@ast
Application of encapsulated cell technology for retinal degenerative diseases.
@en
P2860
P356
P1476
Application of encapsulated cell technology for retinal degenerative diseases.
@en
P2093
P2860
P304
P356
10.1517/14712598.6.7.717
P407
P577
2006-07-01T00:00:00Z